Affordable Access

Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.

Authors
  • Ganem, G
  • Tubiana-Hulin, M
  • Fumoleau, P
  • Combe, M
  • Misset, J-L
  • Vannetzel, J-M
  • Bachelot, T
  • De Ybarlucea, L R
  • Lotz, V
  • Bendahmane, B
  • Dieras, V
Type
Published Article
Journal
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Publication Date
Nov 01, 2003
Volume
14
Issue
11
Pages
1623–1628
Identifiers
PMID: 14581269
Source
Medline
License
Unknown

Abstract

Docetaxel and doxorubicin is an effective and well-tolerated combination in the neoadjuvant therapy of breast cancer. Future controlled trials are warranted to investigate the best schedules and to correlate response with biological factors.

Report this publication

Statistics

Seen <100 times